Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
新闻稿：Forma Treateutics将于2021年3月30日报告2020年第四季度和年终财务业绩并提供业务更新
Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Forma Treateutics将于2021年3月30日报告2020年第四季度和年终财务业绩并提供最新业务
WATERTOWN, Mass.--(BUSINESS WIRE)--March 23, 2021--
马萨诸塞州沃特敦--(商业资讯)--2021年3月23日--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2020 financial results Tuesday, March 30, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on March 30, 2021, to discuss these financial results and provide a business update.
亚洲网加利福尼亚州圣克拉拉3月30日电专注于罕见血液疾病和癌症的临床阶段生物制药公司Forma Treateutics Holdings，Inc.(纳斯达克代码：FMTX)今天宣布，它将公布2020年第四季度和年终财务业绩，周二，2021年3月30日。Fora管理层将于上午8点主持投资界电话会议。东部时间2021年3月30日，讨论这些财务业绩并提供业务最新情况。
Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 5893542. A live webcast of the conference call will be available in the "News & Investors" section of Forma's website at www.formatherapeutics.com.
投资者可以通过在美国或加拿大拨打(833)301-1146或在国际上拨打(914)987-7386或通过参考会议ID 5893542来参与。此次电话会议的网络直播将在Forma公司网站的“新闻与投资者”栏目中播出，网址为www.formaTreateutics.com。
About Forma Therapeutics
关于Forma Treateutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
Forma Treateutics是一家临床阶段的生物制药公司，专注于新疗法的研究、开发和商业化，以改变罕见血液疾病和癌症患者的生活。我们的研发引擎结合了深刻的生物学洞察力、化学专业知识和临床开发能力，创造出具有不同作用机制的候选药物，专注于具有高度未满足需求的适应症。我们的工作产生了广泛的专有计划组合，有可能为患者带来深远的好处。欲了解更多信息，请访问www.FormaTreateutics.com或通过Twitter@FORMAInc.和LinkedIn关注我们。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005971/en/
在Business wire.com上查看源代码版本：https://www.businesswire.com/news/home/20210323005971/en/
CONTACT: Investor Contact:
联系人：投资者联系人：
Mario Corso, +1 781-366-5726
马里奥·科尔索电话：+1 781-366-5726
Forma Therapeutics, Inc.
Forma治疗公司
mcorso@formatherapeutics.com
邮箱：mcorso@formaTreateutics.com
(END) Dow Jones Newswires
(完)道琼斯通讯社
March 23, 2021 16:41 ET (20:41 GMT)
2021年3月23日东部时间16：41(格林尼治标准时间20：41)
译文内容由第三方软件翻译。